Printer Friendly

Rovio Entertainment's profit up in 2017.

M2 EQUITYBITES-March 5, 2018-Rovio Entertainment's profit up in 2017

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Rovio Entertainment Oyj (HEL:ROVIO), a games-first entertainment company, on Friday reported profit before taxes of EUR26.6m, or diluted EPS of EUR0.27, for 2017, from January 2017 to December 2017.

This was an increase over profit before taxes of EUR15.4m, or diluted EPS of EUR0.14, in 2016.

Revenues for the year increased by 55% to EUR297.2m, as compared with EUR191.7m in 2016. Revenues in Games grew by 55.9% in 2017 to EUR248.0m, as compared with EUR159.0m in 2016. Brand Licensing revenues for the year were up by 50.5% to EUR49.2m, as compared with EUR32.7m in 2016.

Also, the company provided outlook for 2018 and expects revenues to be EUR260m to EUR300m, as compared with EUR297m in 2017.

In addition, the parent company's distributable funds amount to EUR 129,800,550.68, of which the profit for the period is EUR19,577,177.06. The company's board of directors has proposed to the Annual General Meeting, to be held on 16 April 2018, that a dividend of EUR 0.09 per share be paid, as compared with EUR0.06 for 2016. No dividend will be paid on any treasury shares held by the company.

Reportedly, based on the number of shares as of the balance sheet date, 31 December, 2017, the total amount of the dividend is EUR 7,125,414.75.

Rovio is a games-first entertainment company that creates, develops, and publishes mobile games and acts as a brand licensor in various entertainment and consumer product categories.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 5, 2018
Words:287
Previous Article:Medeon signs asset purchase agreement with Terumo for XPro System bore vascular closure system.
Next Article:Tabuk Pharmaceuticals executes commercial agreement with Renapharma AB for Detremin.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters